Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.89 USD
Change Today -0.62 / -3.18%
Volume 597.6K
MNTA On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Second Half of 2015

Momenta Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported product revenues of USD 19.305 million compared to USD 5.690 million a year ago. Operating loss was USD 2.412 million compared to USD 26.358 million a year ago. Net loss was USD 2.222 million compared to USD 26.156 million a year ago. Basic and diluted loss per share was USD 0.04 compared to USD 0.51 a year ago. The smaller net loss is primarily due to the milestone payments and product revenue earned from the approval and subsequent launch of Glatopa, offset by an increase in operating expenses. For the six months, the company reported product revenues of USD 22.027 million compared to USD 10.502 million a year ago. Operating loss was USD 24.489 million compared to USD 53.982 million a year ago. Net loss was USD 24.099 million compared to USD 53.518 million a year ago. Basic and diluted loss per share was USD 0.41 compared to USD 1.04 a year ago. The company provided guidance that it expects its operating expenses, excluding stock-based compensation and net of collaborative revenues, to be approximately USD 36 to USD 40 million per quarter for the second half of 2015.

Momenta Pharmaceuticals Inc. to Report Q2, 2015 Results on Aug 04, 2015

Momenta Pharmaceuticals Inc. announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 04, 2015

Momenta Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 04, 2015

Momenta Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 04, 2015

Momenta Pharmaceuticals Announces Executive Changes

Momenta Pharmaceuticals Inc. announced that Rick Shea has advised the company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and appointed. Mr. Shea will remain with the company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period prior to his planned retirement in 2016. Momenta has initiated a CFO search. Mr. Shea joined Momenta in October 2003 as Chief Financial Officer and Senior Vice President.

Momenta Pharmaceuticals, Inc. Announces Launch of Glatopa (Glatiramer Acetate Injection)

Momenta Pharmaceuticals Inc. announced that Sandoz has initiated its U.S. launch of once daily Glatopa (glatiramer acetate injection), a generic equivalent of daily COPAXONE 20 mg, developed under a collaboration agreement between Momenta and Sandoz. Glatopa is the first AP-rated substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Under the terms of its collaboration agreement with Sandoz, Momenta will receive a $10.0 million milestone payment upon first commercial sale. Momenta is also eligible to receive up to $120 million in remaining milestone payments upon the achievement of certain U.S. commercial and sales-based milestones for the Glatopa Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa's high quality U.S.-based supply chain and manufacturing process meet rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Sandoz has also introduced a patient support service offering that includes financial support to eligible patients, personalised injection training and 24-hour access to nurses to answer non-clinical questions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $18.89 USD -0.62

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.12 USD -0.09
OraSure Technologies Inc $5.32 USD -0.08
SciClone Pharmaceuticals Inc $7.91 USD +0.05
Spectrum Pharmaceuticals Inc $7.02 USD -0.25
Sucampo Pharmaceuticals Inc $25.29 USD -1.57
View Industry Companies

Industry Analysis


Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.0x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at